{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:16:49Z","timestamp":1790795809256,"version":"4.1.0"},"reference-count":89,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI110173 , AI120698"],"award-info":[{"award-number":["AI110173 , AI120698"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001117","name":"amfAR, The Foundation for AIDS Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001117","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>While modern HIV therapy can effectively suppress viral replication, the persistence of the latent reservoir posits the greatest hurdle to complete cure. The \u201cshock and kill\u201d strategy is under investigation for HIV therapy, aiming to reactivate latent HIV, and subsequently eliminate it through anti-retroviral therapy and host immune function. However, thus far, studies have yielded suboptimal results, stemming from a combination of ineffective latency reversal and poor immune clearance. Concomitantly, studies have now revealed the importance of the BCL-2 anti-apoptotic protein as a critical mediator of infected cell survival, reservoir maintenance and immune evasion in HIV. Furthermore, BCL-2 inhibitors are now recognized for their anti-HIV effects in pre-clinical studies. This minireview aims to examine the intersection of BCL-2 inhibition and current shock and kill efforts, hoping to inform future studies which may ultimately yield a cure for HIV.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1033609","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T09:05:55Z","timestamp":1666256755000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Prime, shock and kill: BCL-2 inhibition for HIV cure"],"prefix":"10.3389","volume":"13","author":[{"given":"Aswath P.","family":"Chandrasekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Badley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"15035","DOI":"10.1038\/nrdp.2015.35","article-title":"HIV Infection","volume":"1","author":"Deeks","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1038\/s41467-019-10884-9","article-title":"Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART","volume":"10","author":"Bachmann","year":"2019","journal-title":"Nat Commun"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20170193","article-title":"Proliferation of latently infected CD4(+) T cells carrying replication-competent HIV-1: Potential role in latent reservoir dynamics","volume":"214","author":"Hosmane","year":"2017","journal-title":"J Exp Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/v13091858","article-title":"The clonal expansion dynamics of the HIV-1 reservoir: Mechanisms of integration site-dependent proliferation and HIV-1 persistence","volume":"13","author":"Yeh","year":"2021","journal-title":"Viruses"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01590-5","article-title":"Research priorities for an HIV cure: International AIDS society global scientific strategy 2021","volume":"27","author":"Deeks","year":"2021","journal-title":"Nat Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/487439a","article-title":"HIV: Shock and kill","volume":"487","author":"Deeks","year":"2012","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97555","article-title":"Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells","volume":"128","author":"Huang","year":"2018","journal-title":"J Clin Invest"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2232","article-title":"Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF","volume":"16","author":"Quigley","year":"2010","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008906","article-title":"Reactivating latent HIV with PKC agonists induces resistance to apoptosis and is associated with phosphorylation and activation of BCL2","volume":"16","author":"French","year":"2020","journal-title":"PloS Pathog"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.immuni.2018.04.004","article-title":"Anti-apoptotic protein BIRC5 maintains survival of HIV-1-Infected CD4(+) T cells","volume":"48","author":"Kuo","year":"2018","journal-title":"Immunity"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1172\/JCI132374","article-title":"BCL-2 antagonism sensitizes cytotoxic T cell-resistant HIV reservoirs to elimination ex vivo","volume":"130","author":"Ren","year":"2020","journal-title":"J Clin Invest"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701113","article-title":"Both HIV-infected and uninfected cells express TRAILshort, which confers TRAIL resistance upon bystander cells within the microenvironment","volume":"200","author":"Nie","year":"2018","journal-title":"J Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00107-19","article-title":"The role of the BCL-2 family of proteins in HIV-1 pathogenesis and persistence","volume":"33","author":"Chandrasekar","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nrc883","article-title":"The Bcl2 family: regulators of the cellular life-or-death switch","volume":"2","author":"Cory","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"a008714","DOI":"10.1101\/cshperspect.a008714","article-title":"Mechanisms of action of bcl-2 family proteins","volume":"5","author":"Shamas-Din","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02798-06","article-title":"Human immunodeficiency virus type 1 protease cleaves procaspase 8 in vivo","volume":"81","author":"Nie","year":"2007","journal-title":"J Virol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201405051","article-title":"Casp8p41 generated by HIV protease kills CD4 T cells through direct bak activation","volume":"206","author":"Sainski","year":"2014","journal-title":"J Cell Biol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02515-10","article-title":"The HIV-1-specific protein Casp8p41 induces death of infected cells through Bax\/Bak","volume":"85","author":"Sainski","year":"2011","journal-title":"J Virol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1086\/653705","article-title":"Intracellular Casp8p41 content is inversely associated with CD4 T cell count","volume":"202","author":"Cummins","year":"2010","journal-title":"J Infect Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2013.0243","article-title":"Short communication: CD4 T cell declines occurring during suppressive antiretroviral therapy reflect continued production of Casp8p41","volume":"30","author":"Cummins","year":"2014","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03179-15","article-title":"Prime, shock, and kill: Priming CD4 T cells from HIV patients with a BCL-2 antagonist before HIV reactivation reduces HIV reservoir size","volume":"90","author":"Cummins","year":"2016","journal-title":"J Virol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00037-18","article-title":"HIV Protease-generated Casp8p41, when bound and inactivated by Bcl2, is degraded by the proteasome","volume":"92","author":"Natesampillai","year":"2018","journal-title":"J Virol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.immuni.2017.09.018","article-title":"CTLA-4(+)PD-1(-) memory CD4(+) T cells critically contribute to viral persistence in antiretroviral therapy-suppressed, SIV-infected rhesus macaques","volume":"47","author":"McGary","year":"2017","journal-title":"Immunity"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2014.188","article-title":"A primary CD4(+) T cell model of HIV-1 latency established after activation through the T cell receptor and subsequent return to quiescence","volume":"9","author":"Kim","year":"2014","journal-title":"Nat Protoc"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1172\/JCI39199","article-title":"Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation","volume":"119","author":"Yang","year":"2009","journal-title":"J Clin Invest"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01617-15","article-title":"HIV Integration site analysis of cellular models of HIV latency with a probe-enriched next-generation sequencing assay","volume":"90","author":"Sunshine","year":"2016","journal-title":"J Virol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20181454","article-title":"NK cells switch from granzyme b to death receptor-mediated cytotoxicity during serial killing","volume":"216","author":"Prager","year":"2019","journal-title":"J Exp Med"},{"key":"B28","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.158.12.5783","article-title":"Bcl-2 prevents apoptosis induced by perforin and granzyme b, but not that mediated by whole cytotoxic lymphocytes","volume":"158","author":"Sutton","year":"1997","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1202192","article-title":"Inhibition of fas-induced apoptosis by bcl-2","volume":"17","author":"Kawahara","year":"1998","journal-title":"Oncogene"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205258","article-title":"Inhibition of TRAIL-induced apoptosis by bcl-2 overexpression","volume":"21","author":"Fulda","year":"2002","journal-title":"Oncogene"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0274-9","article-title":"CD8(+) T cells in HIV control, cure and prevention","volume":"20","author":"Collins","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1294","article-title":"Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity","volume":"104","author":"Mirandola","year":"2004","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2011.03426.x","article-title":"Cytotoxic T lymphocyte perforin and fas ligand working in concert even when fas ligand lytic action is still not detectable","volume":"133","author":"Hassin","year":"2011","journal-title":"Immunology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/nri3839","article-title":"Perforin and granzymes: Function, dysfunction and human pathology","volume":"15","author":"Voskoboinik","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.10.1391","article-title":"Granzyme b-mediated cytochrome c release is regulated by the bcl-2 family members bid and bax","volume":"192","author":"Heibein","year":"2000","journal-title":"J Exp Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.7.3953","article-title":"BCL-2 blocks perforin-induced nuclear translocation of granzymes concomitant with protection against the nuclear events of apoptosis","volume":"274","author":"Jans","year":"1999","journal-title":"J Biol Chem"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.12.2375","article-title":"Natural killer (NK) cell-mediated cytotoxicity: Differential use of TRAIL and fas ligand by immature and mature primary human NK cells","volume":"188","author":"Zamai","year":"1998","journal-title":"J Exp Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1128\/jvi.70.1.199-206.1996","article-title":"Upregulation of fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes","volume":"70","author":"Badley","year":"1996","journal-title":"J Virol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1172\/JCI1171","article-title":"The expression of fas ligand by macrophages and its upregulation by human immunodeficiency virus infection","volume":"101","author":"Dockrell","year":"1998","journal-title":"J Clin Invest"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nature07606","article-title":"The fas-FADD death domain complex structure unravels signalling by receptor clustering","volume":"457","author":"Scott","year":"2009","journal-title":"Nature"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nature08229","article-title":"XIAP discriminates between type I and type II FAS-induced apoptosis","volume":"460","author":"Jost","year":"2009","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0813","article-title":"Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction","volume":"10","author":"Singh","year":"2020","journal-title":"Cancer Discov"},{"key":"B43","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1182\/blood.2019002121","article-title":"Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity","volume":"135","author":"Dufva","year":"2020","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.26.14871","article-title":"Activation of fas by FasL induces apoptosis by a mechanism that cannot be blocked by bcl-2 or bcl-x(L)","volume":"96","author":"Huang","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"B45","article-title":"Bcl-x and bcl-2 inhibit TNF and fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells","volume":"10","author":"J\u00e4\u00e4ttel\u00e4","year":"1995","journal-title":"Oncogene"},{"key":"B46","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/intimm\/8.7.991","article-title":"Bcl-2 protects against fas-based but not perforin-based T cell-mediated cytolysis","volume":"8","author":"Lee","year":"1996","journal-title":"Int Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1110358108","article-title":"Fas-mediated neutrophil apoptosis is accelerated by bid, bak, and bax and inhibited by bcl-2 and mcl-1","volume":"108","author":"Croker","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1084\/jem.190.2.253","article-title":"Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced fas ligand transcription","volume":"190","author":"Srivastava","year":"1999","journal-title":"J Exp Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)80211-3","article-title":"FADD\/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2","volume":"12","author":"Sprick","year":"2000","journal-title":"Immunity"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1038\/s41467-022-29205-8","article-title":"CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity","volume":"13","author":"Joung","year":"2022","journal-title":"Nat Commun"},{"key":"B51","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12943-022-01516-w","article-title":"BCL-2 expression promotes immunosuppression in chronic lymphocytic leukemia by enhancing regulatory T cell differentiation and cytotoxic T cell exhaustion","volume":"21","author":"Liu","year":"2022","journal-title":"Mol Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20081398","article-title":"Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection","volume":"205","author":"Jones","year":"2008","journal-title":"J Exp Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/QAI.0000000000001887","article-title":"PD-1 expression in HIV-specific CD8+ T cells before antiretroviral therapy is associated with HIV persistence","volume":"80","author":"Ghiglione","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B54","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.chom.2017.12.004","article-title":"Getting the \u201cKill\u201d into \u201cShock and kill\u201d: Strategies to eliminate latent HIV","volume":"23","author":"Kim","year":"2018","journal-title":"Cell Host Microbe"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/v13091750","article-title":"Therapeutic potential of IL-15 and n-803 in HIV\/SIV infection","volume":"13","author":"Harwood","year":"2021","journal-title":"Viruses"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00012-17","article-title":"Maintenance of the HIV reservoir is antagonized by selective BCL2 inhibition","volume":"91","author":"Cummins","year":"2017","journal-title":"J Virol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13370","article-title":"Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding","volume":"173","author":"Song","year":"2016","journal-title":"Br J Pharmacol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00138-21","article-title":"The combination of venetoclax and ixazomib selectively and efficiently kills HIV-infected cell lines but has unacceptable toxicity in primary cell models","volume":"95","author":"Alto","year":"2021","journal-title":"J Virol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134882","article-title":"Preclinical efficacy and biological effects of venetoclax and ixazomib in combination in lymphoma cells","volume":"136","author":"Cosenza","year":"2020","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-792150","article-title":"Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients","volume":"130","author":"Cyrenne","year":"2017","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-104141","article-title":"TLR9 engagement on CD4 T lymphocytes represses gamma-radiation-induced apoptosis through activation of checkpoint kinase response elements","volume":"111","author":"Zheng","year":"2008","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.598319","article-title":"In vitro sensitivity to venetoclax and microenvironment protection in hairy cell leukemia","volume":"11","author":"Vereertbrugghen","year":"2021","journal-title":"Front Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-1951-3","article-title":"Systemic HIV and SIV latency reversal via non-canonical NF-\u03baB signalling in vivo","volume":"578","author":"Nixon","year":"2020","journal-title":"Nature"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2012.04.023","article-title":"Inhibition of bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells","volume":"84","author":"Chen","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201344238","article-title":"IL-15 regulates bcl-2 family members bim and mcl-1 through JAK\/STAT and PI3K\/AKT pathways in T cells","volume":"44","author":"Shenoy","year":"2014","journal-title":"Eur J Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2794","article-title":"Combining T-cell-based immunotherapy with venetoclax elicits synergistic cytotoxicity to b-cell lines in vitro","volume":"38","author":"Murakami","year":"2020","journal-title":"Hematol Oncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"108497","DOI":"10.1016\/j.intimp.2021.108497","article-title":"Venetoclax enhances NK cell killing sensitivity of AML cells through the NKG2D\/NKG2DL activation pathway","volume":"104","author":"Wu","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/2159-8290.CD-19-0759","article-title":"Venetoclax increases intratumoral effector T cells and antitumor efficacy in combination with immune checkpoint blockade","volume":"11","author":"Kohlhapp","year":"2021","journal-title":"Cancer Discov"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.608167","article-title":"Pre-sensitization of malignant b cells through venetoclax significantly improves the cytotoxic efficacy of CD19.CAR-T cells","volume":"11","author":"Yang","year":"2020","journal-title":"Front Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006575","article-title":"In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell \u201ckick\u201d and \u201ckill\u201d in strategy for virus eradication","volume":"13","author":"Marsden","year":"2017","journal-title":"PloS Pathog"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001064","article-title":"Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy","volume":"30","author":"Guti\u00e9rrez","year":"2016","journal-title":"Aids"},{"key":"B72","doi-asserted-by":"publisher","first-page":"101225","DOI":"10.1016\/j.eclinm.2021.101225","article-title":"Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo","volume":"42","author":"Cummins","year":"2021","journal-title":"EClinicalMedicine"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1172\/JCI92684","article-title":"Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency","volume":"127","author":"Archin","year":"2017","journal-title":"J Clin Invest"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(14)70014-1","article-title":"Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1\/2, single group, clinical trial","volume":"1","author":"Rasmussen","year":"2014","journal-title":"Lancet HIV"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00418","article-title":"In vivo effects of romidepsin on T-cell activation, apoptosis and function in the BCN02 HIV-1 Kick&Kill clinical trial","volume":"11","author":"Ros\u00e1s-Umbert","year":"2020","journal-title":"Front Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(21)00239-1","article-title":"Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial","volume":"3","author":"Gruell","year":"2022","journal-title":"Lancet Microbe"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix201","article-title":"Short-course toll-like receptor 9 agonist treatment impacts innate immunity and plasma viremia in individuals with human immunodeficiency virus infection","volume":"64","author":"Vibholm","year":"2017","journal-title":"Clin Infect Dis"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-1946-0","article-title":"Robust and persistent reactivation of SIV and HIV by n-803 and depletion of CD8(+) cells","volume":"578","author":"McBrien","year":"2020","journal-title":"Nature"},{"key":"B79","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41591-021-01651-9","article-title":"Safety and virologic impact of the IL-15 superagonist n-803 in people living with HIV: a phase 1 trial","volume":"28","author":"Miller","year":"2022","journal-title":"Nat Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-4818","article-title":"HIV Nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells","volume":"107","author":"Betts","year":"2006","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.4A0915-422R","article-title":"Elite controller CD8+ T cells exhibit comparable viral inhibition capacity, but better sustained effector properties compared to chronic progressors","volume":"100","author":"Shasha","year":"2016","journal-title":"J Leukoc Biol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1302090110","article-title":"Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation","volume":"110","author":"Marras","year":"2013","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B83","doi-asserted-by":"publisher","first-page":"54","DOI":"10.4049\/jimmunol.2100367","article-title":"Combination immune checkpoint blockade enhances IL-2 and CD107a production from HIV-specific T cells ex vivo in people living with HIV on antiretroviral therapy","volume":"208","author":"Chiu","year":"2022","journal-title":"J Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2017.09.002","article-title":"Antibodies targeting BTLA or TIM-3 enhance HIV-1 specific T cell responses in combination with PD-1 blockade","volume":"183","author":"Grabmeier-Pfistershammer","year":"2017","journal-title":"Clin Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002919","article-title":"The impact of immune checkpoint therapy on the latent reservoir in HIV-infected individuals with cancer on antiretroviral therapy","volume":"35","author":"Lau","year":"2021","journal-title":"Aids"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00361","article-title":"Advances in developing CAR T-cell therapy for HIV cure","volume":"11","author":"Qi","year":"2020","journal-title":"Front Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav5685","article-title":"Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model","volume":"11","author":"Anthony-Gonda","year":"2019","journal-title":"Sci Transl Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.141502","article-title":"Stem cell-derived CAR T cells traffic to HIV reservoirs in macaques","volume":"6","author":"Barber-Axthelm","year":"2021","journal-title":"JCI Insight"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150211","article-title":"Broadly neutralizing antibody-derived CAR T cells reduce viral reservoir in individuals infected with HIV-1","volume":"131","author":"Liu","year":"2021","journal-title":"J Clin Invest"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1033609\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T07:30:01Z","timestamp":1678347001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1033609\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":89,"alternative-id":["10.3389\/fimmu.2022.1033609"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1033609","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,20]]},"article-number":"1033609"}}